EMR POLYMERS LIMITED
Company number 06455767 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: EMR POLYMERS LIMITED
Financial Health Score: A (Provisional)
Explanation: This score is based on the company’s strong compliance record, significant capital base, and active, well-structured governance. However, it is provisional because no detailed financial statements (turnover, profit, assets/liabilities) are available in the provided data. A full diagnosis would require actual balance sheet and profit & loss figures.
Key Vital Signs (Based on Available Data)
| Vital Sign | Finding | Interpretation |
|---|---|---|
| Compliance Health | Accounts and confirmation statement up to date; no overdue filings. | ✅ Normal – no warning signs of administrative distress. |
| Capital Structure | Share capital £13,743,988.34 – very high for a private company. | ✅ Strong – suggests significant shareholder investment or retained equity. |
| Ownership Stability | Single corporate PSC (Invenens Limited) owning >75% of shares. | ⚠️ Controlled – typical of a wholly-owned subsidiary; may be reliant on parent for strategic/financial support. |
| Activity Status | Active, with current directors and secretary. | ✅ Alive – no signs of dormancy, dissolution, or insolvency proceedings. |
| Recent Name Change | Changed from MBA POLYMERS UNITED KINGDOM LIMITED on 18 June 2026. | 🔄 Recent rebrand – could indicate restructuring, new ownership, or strategic pivot. |
| Industry Sector | Manufacture of plastic products (22290) and recycling of sorted materials (38320). | ✅ Sector resilience – demand for recycled plastics is growing, but subject to raw material price volatility and regulatory changes. |
Missing Vital Signs (Critical Gaps)
- Turnover / Revenue – no indication of income level or growth.
- Profitability – no P&L data to assess margins or retained earnings.
- Liquidity – no current assets or liabilities to calculate working capital.
- Net Assets – cannot compute equity cushion or gearing.
- Cash Flow – no cash or debt information.
Diagnosis: Inconclusive but Favourable Outlook
Primary Condition: The company shows no crisis symptoms – no overdue filings, no insolvency flags, active directors, and a substantial capital base. This is like a patient with a strong heartbeat, clear lungs, and good blood pressure, but whose blood work and internal scans are not yet available. The underlying structure suggests a well-capitalised, compliant entity likely operating as a subsidiary of Invenens Limited.
Potential Hidden Issues: - Dependency risk – 100% control by a single corporate owner may limit strategic flexibility. - Name change recency – could mask a past operational change, merger, or even a distressed rebrand. Without historical financial data, we cannot rule out prior financial strain. - Subsidiary transparency – group support can mask weak standalone solvency.
Recommendations (Based on Available Data)
-
Obtain Full Financial Statements – Request the latest filed annual accounts (available from Companies House) to assess liquidity, profitability, and net asset strength. Without these, any assessment is incomplete.
-
Monitor the PSC Relationship – If the parent company (Invenens Limited) shows signs of financial weakness, the subsidiary could be at risk. Check the parent’s own filings.
-
Review the Name Change Rationale – Investigate why MBA POLYMERS UNITED KINGDOM LIMITED changed name. Confirm it was a simple rebrand and not a result of reputational damage, legal action, or restructuring to hide past underperformance.
-
Stress-Test Liquidity – Even with high share capital, if the company has large current liabilities or poor cash conversion, working capital could be tight. Ask management for aged debtor/creditor reports.
-
Check Industry Benchmarks – Compare turnover per employee (if staff numbers become available) and gross margins against SIC 22290 and 38320 averages to gauge competitive health.